Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
APDN 
Applied DNA Sciences Inc (APDN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: APDN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.5
1 Year Target Price $1.5
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -83.21% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.12M USD | Price to earnings Ratio - | 1Y Target Price 1.5 |
Price to earnings Ratio - | 1Y Target Price 1.5 | ||
Volume (30-day avg) 1 | Beta -0.04 | 52 Weeks Range 3.11 - 1410.00 | Updated Date 08/28/2025 |
52 Weeks Range 3.11 - 1410.00 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -57.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When - | Estimate -37.5 | Actual -33.41 |
Profitability
Profit Margin - | Operating Margin (TTM) -1213.58% |
Management Effectiveness
Return on Assets (TTM) -64.06% | Return on Equity (TTM) -137.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2737664 | Price to Sales(TTM) 1.1 |
Enterprise Value -2737664 | Price to Sales(TTM) 1.1 | ||
Enterprise Value to Revenue 0.88 | Enterprise Value to EBITDA -0.34 | Shares Outstanding 519000 | Shares Floating 1291439 |
Shares Outstanding 519000 | Shares Floating 1291439 | ||
Percent Insiders 1.11 | Percent Institutions 6.92 |
Upturn AI SWOT
Applied DNA Sciences Inc
Company Overview
History and Background
Applied DNA Sciences Inc. was founded in 1983. Initially focused on agricultural applications of DNA technology, it has evolved to provide DNA-based security and authentication solutions across various industries.
Core Business Areas
- DNA Tagging & Authentication: This segment focuses on using DNA markers to tag and authenticate products, ensuring traceability and preventing counterfeiting.
- Molecular Diagnostics: This segment develops and markets DNA-based diagnostic tests for various applications, including COVID-19 and other infectious diseases.
- Biotherapeutic Contract Manufacturing Services: DNA plasmid DNA manufacturing contract manufacturing services.
Leadership and Structure
Dr. James A. Hayward is the President and CEO. The company has a traditional corporate structure with departments for R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- SigNature DNA: A DNA-based tagging system used for product authentication and supply chain security. Competitors include Authentix and OpSec Security. Market share data is difficult to determine precisely, but Applied DNA Sciences is a significant player in niche markets such as textile and pharmaceutical authentication. Revenue from this product is not publicly broken out.
- LinearDNA: A PCR-based DNA used in IVD assay development, biotherapeutic manufacturing, gene editing and synthetic biology. Competitors include Twist Bioscience and Codex DNA, but this product is unique since it is manufactured by enzymatic DNA synthesis instead of fermentation based microbial replication. Revenue from this product is not publicly broken out.
- COVID-19 Testing: PCR-based diagnostic tests for COVID-19 detection. This segment is volatile and is subsiding. Competitors include Abbott Laboratories and Thermo Fisher Scientific. Revenue from this product is not publicly broken out.
Market Dynamics
Industry Overview
The authentication and molecular diagnostics industries are growing, driven by increasing concerns about counterfeiting, supply chain security, and the need for rapid and accurate diagnostic testing.
Positioning
Applied DNA Sciences Inc. holds a unique position with its DNA-based solutions, offering a strong value proposition for companies seeking advanced authentication and traceability. Their focus on specialized niches gives them a competitive edge.
Total Addressable Market (TAM)
The TAM for DNA-based product authentication and molecular diagnostics is estimated to be in the billions of dollars globally. Applied DNA Sciences is positioned to capture a portion of this market through its specialized solutions.
Upturn SWOT Analysis
Strengths
- Proprietary DNA technology
- Strong IP portfolio
- Established partnerships
- Reputation for innovation
Weaknesses
- Limited financial resources
- Reliance on key partnerships
- Volatile revenue streams
- Relatively small scale compared to competitors
Opportunities
- Expanding into new markets
- Developing new applications for DNA technology
- Increasing demand for supply chain security
- Growth in the molecular diagnostics market
Threats
- Competition from larger companies
- Technological advancements by competitors
- Regulatory changes
- Economic downturn
Competitors and Market Share
Key Competitors
- ILMN
- TMO
- ABT
Competitive Landscape
Applied DNA Sciences Inc. differentiates itself through its focus on DNA-based solutions. However, it faces stiff competition from larger, more established companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been uneven, with periods of rapid growth followed by declines, often tied to specific projects or market opportunities (e.g., COVID-19 testing).
Future Projections: Analyst projections vary, but generally anticipate growth driven by increasing adoption of DNA-based authentication and continued development of new diagnostic applications. Exact figures are contingent upon analyst ratings at any given time.
Recent Initiatives: Recent initiatives include expanding partnerships for DNA tagging in new industries and developing new diagnostic tests.
Summary
Applied DNA Sciences Inc. is a niche player with innovative DNA-based solutions. While its technology offers a unique value proposition, the company struggles with financial stability and faces strong competition. Strategic partnerships and expansion into new markets are crucial for future success and volatility and limited capital are points to watch out for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Investor Presentations, Press Releases, Market Research Reports, Analyst Reports.
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data and TAM estimates are approximate and may vary based on different sources. Financial data may be outdated. Conduct your own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Applied DNA Sciences Inc
Exchange NASDAQ | Headquaters Stony Brook, NY, United States | ||
IPO Launch date 2003-07-15 | President, CEO, Chairperson & Secretary Ms. Judith Murrah | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 46 | Website https://www.adnas.com |
Full time employees 46 | Website https://www.adnas.com | ||
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. The company was founded in 1983 and is headquartered in Stony Brook, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.